<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="417">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105467</url>
  </required_header>
  <id_info>
    <org_study_id>5172-060</org_study_id>
    <secondary_id>2014-000137-22</secondary_id>
    <nct_id>NCT02105467</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)</brief_title>
  <official_title>A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir
      (MK-8742) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype (GT)
      1, 4, or 6 infection. Participants will be randomly assigned (3:1 ratio) to immediate
      treatment or deferred treatment (placebo control). The primary efficacy hypothesis is that
      the proportion of participants receiving combination therapy in the Immediate Treatment Arm
      who achieve sustained viral response at 12 weeks after the end of study treatment (SVR12)
      will be superior to 73%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)</measure>
    <time_frame>Week 24 (12 weeks after the end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR12 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 12 weeks after the end of all study therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing at Least One Adverse Event</measure>
    <time_frame>Up to Week 14 (14 days after the initial treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinued From Study Treatment Because of an Adverse Event</measure>
    <time_frame>Up to Week 12 (end of initial treatment period)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks After the End of Treatment (SVR24)</measure>
    <time_frame>Week 36 (24 weeks after the end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR24 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 24 weeks after the end of all study therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response at 4 Weeks After the End of Treatment (SVR4)</measure>
    <time_frame>Week 16 (4 weeks after the end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR4 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 4 weeks after the end of all study therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Immediate Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablet orally, once per day (QD) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo to grazoprevir 100 mg/elbasvir 50 mg FDC tablet orally, QD for 12 weeks; after a 4-week unblinding period participants will receive open label grazoprevir 100 mg/elbasvir 50 mg FDC tablet orally, QD for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir 100mg/Elbasvir 50 mg FDC</intervention_name>
    <arm_group_label>Immediate Treatment</arm_group_label>
    <arm_group_label>Deferred Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to grazoprevir + elbasvir FDC</intervention_name>
    <arm_group_label>Deferred Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Documented chronic HCV GT1, GT4, or GT6 with no evidence of non-typeable or mixed
             genotype infection (positive for anti-HCV antibody, HCV RNA, or any of the listed GTs
             at least 6 months prior to screening must be confirmed by screening lab results)

          -  Cirrhosis defined by: liver biopsy showing cirrhosis METAVIR F4; or Fibroscan showing
             cirrhosis with a result of &gt;12.5 kiloPascals (kPa); or FibroSure® (Fibrotest®) score
             of &gt;0.75 and an aspartate aminotransferase (AST): platelet ratio index (APRI) of &gt;2

          -  Absence of cirrhosis defined by: liver biopsy showing absence of cirrhosis, or
             Fibroscan with a result of ≤12.5 kPa, or Fibrosure® (Fibrotest®) score of &lt;= 0.48 and
             APRI of &lt;=1

          -  HCV treatment status of treatment naïve (naïve to all anti-HCV treatment) and can
             also be ineligible to take pegylated interferon

          -  Female participant not of reproductive potential, or female of reproductive potential
             and agrees to avoid becoming pregnant while receiving study drug and for 14 days
             after the last dose of study drug (using abstinence or acceptable methods of
             contraception)

        Exclusion criteria:

          -  Evidence of decompensated liver disease manifested by the presence of or history of
             ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver disease. For cirrhotics, participants who are
             Child-Pugh Class B or C or who have a Pugh-Turcotte (CPT) score &gt;6

          -  Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

          -  History of malignancy &lt;=5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
             or carcinoma in situ; or is under evaluation for other active or suspected malignancy

          -  Evidence of hepatocellular carcinoma (HCC) or under evaluation for HCC

          -  Currently participating or has participated in a study with an investigational
             compound within 30 days of signing informed consent and is not willing to refrain
             from participating in another such study during the course of this study

          -  Clinically-relevant drug or alcohol abuse within 12 months of screening

          -  Pregnant, breast-feeding, or expecting to conceive or donate eggs from Day 1
             throughout treatment and 14 days after the last dose of study medication or longer if
             dictated by local regulations

          -  Organ transplant (including hematopoietic stem cell transplants) other than cornea
             and hair

          -  Poor venous access

          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption
             disorder (e.g., celiac sprue disease)

          -  Any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids, TNF antagonists, or other immunosuppressant drugs
             during the course of the trial

          -  Evidence of history of chronic hepatitis not caused by HCV, including but not limited
             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune
             hepatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.</citation>
    <PMID>25909356</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <firstreceived_results_date>February 3, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The current disclosure covers up to 12 weeks after completion of blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination tablet (Immediate Treatment) and up to 14 days after completion of blinded placebo tablet (Deferred Treatment). Data cut-off date for this initial disclosure was 26 February 2015; analysis of SVR24 data is ongoing.</recruitment_details>
      <pre_assignment_details>A total of 469 participants were screened and 421 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Immediate Treatment</title>
          <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Deferred Treatment</title>
          <description>Participants received blinded placebo tablet once daily for 12 weeks; after a 4-week unblinding period participants received open-label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing data analysis</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immediate Treatment</title>
          <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Deferred Treatment</title>
          <description>Participants received blinded placebo tablet once daily for 12 weeks; after a 4-week unblinding period participants received open-label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="316"/>
                <measurement group_id="B2" value="105"/>
                <measurement group_id="B3" value="421"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.2" spread="11.1"/>
                <measurement group_id="B2" value="53.8" spread="11.2"/>
                <measurement group_id="B3" value="52.6" spread="11.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="194"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="171"/>
                <measurement group_id="B2" value="56"/>
                <measurement group_id="B3" value="227"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Genotype 1a</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="157"/>
                <measurement group_id="B2" value="54"/>
                <measurement group_id="B3" value="211"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Genotype 1b</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="131"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="171"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Genotype 4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Genotype 6</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)</title>
        <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR12 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 12 weeks after the end of all study therapy.</description>
        <time_frame>Week 24 (12 weeks after the end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Full Analysis Set included randomized participants who received at least one dose of study treatment. This outcome measure applied only to the Immediate Treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Treatment</title>
            <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="316"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)</title>
            <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR12 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 12 weeks after the end of all study therapy.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94.6" lower_limit="91.5" upper_limit="96.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Superiority of SVR12 in the Immediate Treatment group was tested against the historical response rate of 73%.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>One-sided, one-sample exact test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing at Least One Adverse Event</title>
        <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
        <time_frame>Up to Week 14 (14 days after the initial treatment period)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The All Subjects as Treated population included randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Treatment</title>
            <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Deferred Treatment</title>
            <description>Participants received blinded placebo tablet once daily for 12 weeks; after a 4-week unblinding period participants received open-label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="316"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Experiencing at Least One Adverse Event</title>
            <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinued From Study Treatment Because of an Adverse Event</title>
        <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
        <time_frame>Up to Week 12 (end of initial treatment period)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The All Subjects as Treated population included randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Treatment</title>
            <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Deferred Treatment</title>
            <description>Participants received blinded placebo tablet once daily for 12 weeks; after a 4-week unblinding period participants received open-label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="316"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Discontinued From Study Treatment Because of an Adverse Event</title>
            <description>An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks After the End of Treatment (SVR24)</title>
        <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR24 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 24 weeks after the end of all study therapy.</description>
        <time_frame>Week 36 (24 weeks after the end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>07/2016</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response at 4 Weeks After the End of Treatment (SVR4)</title>
        <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR4 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 4 weeks after the end of all study therapy</description>
        <time_frame>Week 16 (4 weeks after the end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Full Analysis Set included randomized participants who received at least one dose of study treatment. This outcome measure applied only to the Immediate Treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Treatment</title>
            <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="316"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Achieving Sustained Virologic Response at 4 Weeks After the End of Treatment (SVR4)</title>
            <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR4 was defined as HCV RNA &lt;Lower Limit of Quantitation (&lt;15 IU/mL) 4 weeks after the end of all study therapy</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97.2" lower_limit="94.7" upper_limit="98.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after the last dose of blinded study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Immediate Treatment</title>
          <description>Participants received blinded grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Deferred Treatment</title>
          <description>Participants received blinded placebo tablet once daily for 12 weeks; after a 4-week unblinding period participants received open-label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hiatus hernia strangulated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="316"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="316"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="51" subjects_affected="48" subjects_at_risk="316"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="316"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="316"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="62" subjects_affected="52" subjects_at_risk="316"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="316"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme, Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
